Status:
UNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
2-17 years
Brief Summary
This is a prospective pilot study to assess the plasma levels of particular proteins involved in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP, as well as mi...
Detailed Description
Aim 1: This study will correlate proteins in the TGF- β signaling pathway and micro RNA levels with invasive (catheterization) and non-invasive (echocardiography) measurements of pulmonary artery pres...
Eligibility Criteria
Inclusion
- Pediatric subjects ages 2-17 years
- Subjects undergoing a clinically indicated cardiac catheterization.
- Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†
- Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure \>20mmHg, pulmonary vascular resistance index \>3 Woods units\*m2, and wedge pressures \<15mmHg.
- Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria.
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04489251
Start Date
July 1 2020
End Date
January 1 2023
Last Update
November 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226